Dova is a growing specialty pharmaceutical company driven by our passion for building a high-value portfolio of differentiated medicines for patients with rare diseases. Every day we work to develop and commercialize solutions that can improve the health and well-being of patients in this community.
Our company was founded in 2016 to commercialize DOPTELET® (avatrombopag) for the treatment of thrombocytopenia, or low platelet counts in the blood. DOPTELET is an oral thrombopoietin (TPO) receptor agonist administered with food. Prescribers Information.
In May 2018, DOPTELET received its initial FDA approval for the treatment of thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo a procedure. DOPTELET can raise platelet levels in CLD patients with thrombocytopenia ahead of an invasive procedure, offering an effective alternative to platelet transfusions. The EMA approved DOPTELET in the European Union for this indication the following year.
In June 2019, DOPTELET was approved by the FDA for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Chronic ITP is a rare autoimmune bleeding disorder, affecting approximately 60,000 adults in the United States.
Swedish Orphan Biovitrum AB (publ) (Sobi), a specialized international biopharmaceutical company transforming the lives of people with rare diseases, acquired Dova in November 2019. We are a wholly-owned subsidiary of the company. Read our corporate governance documents to learn more about how we conduct our business with honesty and integrity.